Cours suspendu

Autres langues SpringWorks Therapeutics, Inc.

Actions

SWTX

US85205L1070

Produits pharmaceutiques

Temps Différé Nasdaq Autres places de cotation 22:00:00 30/06/2025			Varia. 5j.	Varia. 1 janv.
46,99 ^USD	+0,02%		-.--%	-

15/12	Immunome bondit après des résultats prometteurs pour son traitement contre les tumeurs desmoïdes
01/12	Tyra Bioscience nomme Bhavesh Ashar au poste de directeur des opérations	MT

Autres langues

15/12	Immunome jumps after promising results for its desmoid tumor treatment
01/12	Tyra Bioscience Appoints Bhavesh Ashar as Chief Operating Officer
10/11	Edgewise Therapeutics Hires Michael Nofi as CFO
21/10/25	SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
21/10/25	SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
18/08/25	Springworks Therapeutics Gets European Commission Approval for Ogsiveo in Desmoid Tumors
18/08/25	European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
18/08/25	European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
18/08/25	SpringWorks Therapeutics, Inc. Announces European Commission Grants Approval of OGSIVEO (nirogacestat) for the Treatment of Adults with Desmoid Tumors
18/07/25	European Commission Grants Conditional Approval of Ezmekly® (Mirdametinib) for the Treatment of Adult and Pediatric Patients with Nf1-Pn
18/07/25	European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
18/07/25	European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
02/07/25	SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from S&P Biotechnology Select Industry Index
02/07/25	SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from S&P Global BMI Index
02/07/25	SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from S&P TMI Index
01/07/25	Merck KGaA completed the acquisition of SpringWorks Therapeutics, Inc. from FMR LLC, The Vanguard Group, Inc. and BlackRock, Inc. and others.
01/07/25	Springworks-Deal bringt Merck für Langfristprognose in die Spur
01/07/25	Merck schließt größten Pharma-Deal seit Jahrzehnten ab
01/07/25	Germany's Merck KGaA Closes $3.4 Billion Purchase of US-based SpringWorks
01/07/25	Merck schließt Übernahme von Springworks ab - Lotet weitere Zukäufe aus
01/07/25	Merck schließt Übernahme von Springworks Therapeutics ab
01/07/25	SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from NASDAQ Composite Index
30/06/25	SpringWorks Therapeutics, Inc.(NasdaqGM:SWTX) dropped from Russell Small Cap Comp Growth Benchmark
30/06/25	SpringWorks Therapeutics, Inc.(NasdaqGM:SWTX) dropped from Russell 3000E Growth Benchmark
30/06/25	SpringWorks Therapeutics, Inc.(NasdaqGM:SWTX) dropped from Russell 3000 Growth Benchmark